Selro Announces New Integration with Rackhams to Empower Multi-Channel Luxury Retailers
Selro Announces New Integration with Rackhams to Empower Multi-Channel Luxury Retailers
READING, BERKSHIRE, UNITED KINGDOM, June 3, 2025 / EINPresswire.com / -- Selro, a leading multi-channel eCommerce management platform, is pleased to announce its latest integration with Rackhams, the luxury department store marketplace. This new integration enables online sellers to efficiently manage their Rackhams inventory and orders directly through the Selro platform.
With Rackhams' growing reputation as a destination for premium brands and curated shopping experiences, this integration offers Selro users a valuable opportunity to access a high-end customer base while streamlining day-to-day operations.
Key Features of the Integration Include:
Real-Time Inventory Sync: Automatically keep stock levels up to date across all connected channels, reducing the risk of overselling
Centralised Order Management: View, process, and fulfil Rackhams orders from the same dashboard used for other marketplaces and webstores
Manual Price Updates: Easily manage and update Rackhams pricing through Selro's interface, with full control over each listing
'We're excited to welcome Rackhams into our network of supported marketplaces,' said Selro's spokesperson. 'This new integration expands selling opportunities for our users and supports retailers focused on quality, service, and brand value.'
Selro continues to grow its suite of integrations to support multi-channel sellers in scaling their business efficiently. The Rackhams integration reinforces Selro's position as a go-to platform for modern eCommerce operations.
About Selro
Selro is a multi-channel eCommerce management platform designed to simplify and automate the operations of online retailers. From inventory and order management to shipping integrations and reporting, Selro empowers merchants to streamline their business across leading marketplaces including Amazon, eBay, Shopify, Etsy, and more.
About Rackhams
Rackhams is a UK-based online department store and luxury marketplace that offers a curated selection of high-end fashion, home, beauty, and lifestyle products. It provides an exclusive platform for premium brands to connect with discerning shoppers seeking quality and sophistication.
Mary Evans
Selro
+44 118 466 1244
email us here
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
New eurozone rate cut expected as Trump trade war weighs
US President Donald Trump's tariff blitz, persistent growth worries and slowing inflation are expected to prompt eurozone rate-setters to lower borrowing costs again on Thursday. It would be the European Central Bank's seventh consecutive interest rate cut, with officials having shifted focus from taming consumer price rises to easing pressure on the sluggish eurozone economy. Trump's tariffs have added to an already uncertain outlook for the single-currency area, with Europe firmly in his crosshairs, fuelling fears about a heavy hit to the continent's exporters. Expectations that the Frankfurt-based institution will deliver a fresh rate cut were strengthened this week when data showed eurozone inflation eased to 1.9 percent in May, faster than expected and below its two-percent target. "Any doubts about an ECB interest rate cut this week have now been eliminated," said Dirk Schumacher, chief economist at German public lender KfW. Analysts expect another quarter-point reduction that would take the central bank's key deposit rate to two percent. Observers will be on the lookout for any hints from ECB President Christine Lagarde at her press conference that policymakers could hit pause at their next meeting in July, as some expect. The ECB's series of cuts stands in contrast to the US Federal Reserve, which has kept rates on hold recently amid fears that Trump's levies could stoke inflation in the world's top economy. - Questions on Lagarde's future - Lagarde may also face questions on her own future after the Financial Times last week reported she had discussed leaving the ECB early to take the helm of the World Economic Forum, which organises the annual Davos gathering. The ECB has however insisted that Lagarde is "determined" to finish her term, which ends in 2027. Trump, who argues his tariffs will bring manufacturing jobs back to the United States, has already hit the EU with multiple waves of levies. The bloc currently faces a 10-percent "baseline" levy as well as higher duties on specific sectors. He has paused even higher rates on the EU and other trading partners to allow for talks, but he continues to launch fresh salvos that are keeping the world on edge. This week he doubled tariffs on aluminium and steel from 25 to 50 percent and last month threatened the EU with an escalation if it did not negotiate a swift deal. For the ECB, it is a tricky task to protect the eurozone from the mercurial US president's trade policies while keeping inflation stable. The ECB is expected to cut its inflation predictions when it releases its own new economic forecasts Thursday, with most observers now believing that Trump's tariffs will add to downward pressure. - Easing inflation - This is due to factors including tariff-hit China redirecting inexpensive manufactured goods to Europe, recent strengthening of the euro and potentially lower energy prices. The ECB is also likely to cut its growth estimates Thursday due to the impact of the trade war, after the EU slashed its forecasts last month. Lower inflation and slower growth should push the ECB to make further rate cuts, but there are some factors making this uncertain. These include signs of resilience in the eurozone economy at the start of the year and a a potentially inflationary spending blitz planned by the new German government. Given the lack of clarity, ING bank analyst Carsten Brzeski said he believes the ECB would like to take a breather at its next meeting in July. "Unless trade tensions return with a vengeance, our suspicion is that the ECB would like to stick to a wait-and-see approach over the summer," he said. sr/sea/lth Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
21 minutes ago
- Bloomberg
FTSE 100's Winning Run to Be Tested
There was a blow for the London market last night, however, when Cobalt Holdings said it has decided not to proceed with its IPO. The company had been due to debut on Thursday in an offering aimed at raising $230 million. That money was to be used to by physical cobalt from Glencore, which is one of the firm's backers. 'The company intends to explore options, including possibly funding the business privately,' Cobalt Holdings said in a statement to Bloomberg. It had been one of the bright spots in what remains a very quiet market for listings in London, so its decision once again will deliver a hit to any tentative momentum that was building.
Yahoo
24 minutes ago
- Yahoo
Juvenescence acquires AI drug discovery company Ro5 to boost R&D capabilities and drive pipeline of medicines to extend healthy lifespan
Ro5 Inc. acquisition enhances artificial intelligence/machine learning drug discovery capabilities Strategic addition strengthens Juvenescence's AI-enabled therapeutics pipeline and supports partnership with M42 (Mubadala) Acquisition follows $76m Series B-1 financing first-close led by M42 in May 2025 Ramsey, Isle of Man, 5 June 2025: Juvenescence Limited, a clinical stage AI-enabled biotech company, is pleased to announce the acquisition of Ro5 Inc., a proprietary AI drug discovery company. This acquisition enhances Juvenescence's artificial intelligence/machine learning drug discovery capabilities and forms a central component of its strategic partnership with Abu Dhabi-based global healthcare company M42, announced in April 2025. Ro5's platform leverages a proprietary Biomedical Knowledge Graph, comprising over 85 million nodes and approximately 400 million relationships, to uncover novel associations in biological processes and enable a robust evaluation of drug targets based on biological, therapeutic, and market potential. The Company's AI Chemistry Platform incorporates state-of-the art machine learning model and cheminformatics tools, facilitating rapid and efficient discovery and design of novel compounds from hit identification through to lead optimisation. The acquisition of Ro5 follows Juvenescence's recent announcement of a $76 million first-close of its Series B-1 financing round led by cornerstone investor M42, with follow-on investments from existing investors. The second close of the Series B-1 is anticipated in the third quarter of 2025. Proceeds will support clinical milestones and AI-driven development across Juvenescence's portfolio of therapeutics targeting age-related diseases. The integration of Ro5's AI drug discovery platform and expert team into Juvenescence will accelerate the identification and development of AI-enabled therapeutics, reinforcing the company's growing pipeline in cognition, cardio-metabolism, immunity, and cellular Richard Marshall CBE, CEO of Juvenescence, said: 'We are delighted to welcome the Ro5 team and the Company's capabilities into Juvenescence. The addition of Ro5's AI platform significantly enhances our drug discovery capabilities, accelerating our efforts to identify and advance effective therapeutics to extend healthspan. This acquisition is also a critical part of our wider strategy with M42 to deliver a pipeline of transformative therapies and establish a world-class life sciences hub in Abu Dhabi. Together, we remain committed to improving the lives of millions of patients.' Charles Dazler Knuff, CEO of Ro5, added: 'The Ro5 team are thrilled to be joining the world class drug development team at Juvenescence. Embedding our AI-driven drug discovery capabilities into Juvenescence's operations will accelerate their ability to advance next-generation therapeutics. Together with our partners at M42 we are also laying the foundations for a pioneering life sciences ecosystem in Abu Dhabi that leverages AI innovation to transform patient care and global health outcomes.' About Juvenescence Juvenescence is a clinical-stage AI-enabled biotech company developing novel medicines to extend healthy lifespan. Our approach centers around developing medicines that target core aging mechanisms to treat and prevent age-related diseases. It was founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan – with a track record of leading 2 of the 10 largest biopharma deals in the last decade, including the sale of Biohaven to Pfizer for $11.6bn. The Juvenescence team, led by Dr Richard Marshall CBE, consists of world-class R&D leadership that have previously been instrumental in the approval of medicines totalling $30bn in peak annual sales. Powered by an unrivaled drug development team, Juvenescence leverages cutting-edge AI tools to unlock successful therapeutics. The company's diverse, AI-enabled medicines pipeline of clinical and near-clinical stage candidates targeting core ageing mechanisms are in development for cognition, cardio-metabolism, immunity and cellular repair. In addition, Juvenescence has investments in a number of cutting-edge companies and platform technologies focused on AI and regenerative medicine. For more information, visit: About Ro5 In the race to save and improve lives, Ro5 accelerates drug discovery, development, repurposing, and clinical trials. We enrich our client's data with our proprietary database, then use machine learning platforms to reduce discovery time from years to months, increase accuracy, and, at every point, lower costs. Our proprietary state-of-the-art neural network architectures learn the complex relationships between a molecule's basic physicochemical properties and its more general pharmacological characteristics and are real and effective. Investor Relations Contact: juvenescenceir@ Media contact: ICR Healthcare Jessica Hodgson / Chris Welsh Juvenescence@ Forward-Looking Statements Statements in this communication relating to plans, strategies, specific activities, and other statements that are not descriptions of historical facts are forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include any risks detailed from time to time in the Company's reports. Such statements are based on the management's current beliefs and expectations and are subject to significant risks and uncertainties outside of management and the Company's control. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, the Company does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.
